Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 3
Author: Motilal Oswal

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Mid-range Performer

1948.5000 19.20 (1.00%)

NSE Oct 09, 2025 10:08 AM

52.76% Gain from 52W Low

Volume: 155.0K

Glenmark Pharmaceuticals Ltd.

16 Aug 2021

1948.50

1.00%

In-line 1QFY22; DF drives overall earnings growth

Neutral: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

In-line 1QFY22; DF drives overall earnings growth Motilal Oswal values your support in the Asiamoney Brokers Poll 2021 for India Research, Sales, Corporate Access and...

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.